National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cladribine (Mavenclad®) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features

NCPE Assessment Process Ongoing
Rapid review received  22/08/2017
Rapid review completed  18/09/2017
Rapid Review outcome A Full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE  03/10/2017
Pre-submission consultation with Applicant  24/10/2017
Anticipated date of submission  Expected December 2017
Current Status Awaiting applicant submission